Literature DB >> 16113383

Influence of format on in vitro penetration of antibody fragments through porcine cornea.

H M Brereton1, S D Taylor, A Farrall, D Hocking, M A Thiel, M Tea, D J Coster, K A Williams.   

Abstract

AIM: Antibody fragments, appropriately formulated, can penetrate through the ocular surface and thus have potential as therapeutic agents. The aim was to investigate the influence of protein fragment format on the kinetics and extent of ocular penetration in vitro.
METHODS: Immunoglobulin single chain variable domain fragments of a murine monoclonal antibody with specificity for rat CD4 were engineered with a 20 or 11 amino acid linker by assembly polymerase chain reaction, expressed in Escherichia coli and purified by chromatography. Fab fragments of the parental antibody were prepared by papain digestion. Antibody fragments were formulated with a penetration and a viscosity enhancer and were applied to the surface of perfused pig corneas for up to 10 hours in vitro. Penetration was quantified by flow cytometry on rat thymocytes.
RESULTS: 20-mer antibody fragments formed natural monomers and dimers following purification that could be separately isolated, while 11-mer fragments were dimeric. All formats of fragment (20-mer monomers and dimers, 11-mer dimers, Fab) showed penetration through the pig cornea after 6 hours of intermittent topical administration.
CONCLUSION: Antibody fragments of different shapes and sizes can penetrate the cornea after topical administration, thereby increasing the potential of this class of proteins for topical ophthalmic use.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16113383      PMCID: PMC1772801          DOI: 10.1136/bjo.2005.066225

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  28 in total

1.  A simple corneal perfusion chamber for drug penetration and toxicity studies.

Authors:  M A Thiel; N Morlet; D Schulz; H F Edelhauser; J K Dart; D J Coster; K A Williams
Journal:  Br J Ophthalmol       Date:  2001-04       Impact factor: 4.638

2.  Human conjunctiva contains high endothelial venules that express lymphocyte homing receptors.

Authors:  R J Haynes; P J Tighe; R A Scott; H Singh Dua
Journal:  Exp Eye Res       Date:  1999-10       Impact factor: 3.467

3.  Penetration of engineered antibody fragments into the eye.

Authors:  M A Thiel; D J Coster; S D Standfield; H M Brereton; C Mavrangelos; H Zola; S Taylor; A Yusim; K A Williams
Journal:  Clin Exp Immunol       Date:  2002-04       Impact factor: 4.330

4.  [Lymph drainage of the cornea, limbus and conjunctiva].

Authors:  J Grüntzig; S Nolte; P Schad; R Pfankuchen
Journal:  Klin Monbl Augenheilkd       Date:  1987-06       Impact factor: 0.700

5.  Permeability of horseradish peroxidase in the rabbit corneal epithelium.

Authors:  A M Tonjum
Journal:  Acta Ophthalmol (Copenh)       Date:  1974

6.  Importance of the noncorneal absorption route in topical ophthalmic drug delivery.

Authors:  I Ahmed; T F Patton
Journal:  Invest Ophthalmol Vis Sci       Date:  1985-04       Impact factor: 4.799

7.  Simplified preparation of rabbit Fab fragments.

Authors:  A Coulter; R Harris
Journal:  J Immunol Methods       Date:  1983-04-29       Impact factor: 2.303

8.  The dynamics of IgG in the cornea.

Authors:  M Allansmith; A de Ramus; D Maurice
Journal:  Invest Ophthalmol Vis Sci       Date:  1979-09       Impact factor: 4.799

9.  Diffusion across the sclera.

Authors:  D M Maurice; J Polgar
Journal:  Exp Eye Res       Date:  1977-12       Impact factor: 3.467

10.  Authentic T helper CD4 (W3/25) antigen on rat peritoneal macrophages.

Authors:  W A Jefferies; J R Green; A F Williams
Journal:  J Exp Med       Date:  1985-07-01       Impact factor: 14.307

View more
  9 in total

1.  Topical Bevacizumab for the Treatment of Ocular Surface Squamous Neoplasia.

Authors:  Leyla Asena; Dilek Dursun Altınörs
Journal:  J Ocul Pharmacol Ther       Date:  2015-06-26       Impact factor: 2.671

2.  3-hydroxykynurenine suppresses CD4+ T-cell proliferation, induces T-regulatory-cell development, and prolongs corneal allograft survival.

Authors:  Sarah S Zaher; Conrad Germain; Hongmei Fu; Daniel F P Larkin; Andrew J T George
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-04-22       Impact factor: 4.799

Review 3.  Corneal neovascularization and the utility of topical VEGF inhibition: ranibizumab (Lucentis) vs bevacizumab (Avastin).

Authors:  William Stevenson; Sheng-Fu Cheng; Mohammad H Dastjerdi; Giulio Ferrari; Reza Dana
Journal:  Ocul Surf       Date:  2012-01-25       Impact factor: 5.033

4.  Topical Anti-TNFα Agent Licaminlimab (OCS-02) Relieves Persistent Ocular Discomfort in Severe Dry Eye Disease: A Randomized Phase II Study.

Authors:  Lee Shettle; Eugene McLaurin; Joseph Martel; John W Seaman; Georges Weissgerber
Journal:  Clin Ophthalmol       Date:  2022-07-06

5.  Effects of rat anti-VEGF antibody in a rat model of corneal graft rejection by topical and subconjunctival routes.

Authors:  Nicolas Rocher; Francine Behar-Cohen; Jean-Antoine C Pournaras; Marie-Christine Naud; Jean-Claude Jeanny; Laurent Jonet; Jean-Louis Bourges
Journal:  Mol Vis       Date:  2011-01-11       Impact factor: 2.367

6.  A novel protocol of whole mount electro-immunofluorescence staining.

Authors:  Hongshan Liu; Winston W Y Kao
Journal:  Mol Vis       Date:  2009-03-06       Impact factor: 2.367

7.  Pharmacokinetics of bevacizumab after topical and intravitreal administration in human eyes.

Authors:  Elad Moisseiev; Michael Waisbourd; Elad Ben-Artsi; Eliya Levinger; Adiel Barak; Tad Daniels; Karl Csaky; Anat Loewenstein; Irina S Barequet
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2013-10-31       Impact factor: 3.117

8.  Topical Ocular Anti-TNFα Agent Licaminlimab in the Treatment of Acute Anterior Uveitis: A Randomized Phase II Pilot Study.

Authors:  Theodore A Pasquali; Melissa M Toyos; David B Abrams; David K Scales; John W Seaman; Georges Weissgerber
Journal:  Transl Vis Sci Technol       Date:  2022-06-01       Impact factor: 3.048

Review 9.  Toward Drug-Like Multispecific Antibodies by Design.

Authors:  Manali S Sawant; Craig N Streu; Lina Wu; Peter M Tessier
Journal:  Int J Mol Sci       Date:  2020-10-12       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.